Meeting
2018 ASCO Annual Meeting
PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.
Authors
Francois Clement Bidard
Institut Curie, Paris, France
Francois Clement Bidard , Renaud Sabatier , Frederique Berger , Barbara Pistilli , Florence Dalenc , Thibault De La Motte Rouge , Jean-Sebastien Frenel , Coraline Dubot , Sylvain Ladoire , Jean-Marc Ferrero , Laetitia Stefani , Alain Lortholary , Anne-Claire Hardy-Bessard , Julien Grenier , Sibille Everhard , Emmanuelle Jeannot , Charlotte Proudhon , Jérôme Lemonnier , Suzette Delaloge , Thomas Denis Bachelot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT03079011
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS1105)
DOI
10.1200/JCO.2018.36.15_suppl.TPS1105
Abstract #
TPS1105
Poster Bd #
183b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.
First Author: Elgene Lim
Poster
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
First Author: Kelvin K H Bao
Poster
2019 ASCO Annual Meeting
Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.
First Author: Muriel Laine
Poster
2024 ASCO Breakthrough
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
First Author: Joohyuk Sohn